Yep, not bad. Can't help but notice they run a tight ship, but for corporate and admin costs. Wonder where those are being spent and if they might not be basically fixed?
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025